Protein / target

Small ribosomal subunit protein uS19

rpsSP0A7U3Escherichia coli (strain K12)Swiss-Prot
30
Clinical trials
8
Drugs targeting

Protein at a glance

Biological role

Structural constituent of ribosome

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function

In the E.coli 70S ribosome in the initiation state (PubMed:12809609) it has been modeled to contact the 23S rRNA of the 50S subunit forming part of bridge B1a; this bridge is broken in the model with bound EF-G. The 23S rRNA contact site in bridge B1a is modeled to differ in different ribosomal states (PubMed:12859903), contacting alternately S13 or S19. In the 3.5 angstroms resolved ribosome structures (PubMed:16272117) the contacts between L5, S13 and S19 bridge B1b are different, confirming the dynamic nature of this interaction. Bridge B1a is not visible in the crystallized ribosomes due to 23S rRNA disorder

Domains and Gene Ontology detail (7)

Gene Ontology

  • Ccytoplasm
  • Ccytosol
  • Ccytosolic small ribosomal subunit
  • FrRNA binding
  • Fstructural constituent of ribosome
  • FtRNA binding
  • Pcytoplasmic translation

92 aa · 10 kDa

Drugs targeting this protein

8

Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.

Azithromycin
Inhibitor

Bacterial 70S ribosome inhibitor

Acts on a complex — shared with rpsL, rpsR, rpsD +51 more · 1 of 55 recorded protein targets — broad pharmacology

Doxycycline
Inhibitor

Bacterial 70S ribosome inhibitor

Acts on a complex — shared with rpsL, rpsR, rpsD +51 more · 1 of 59 recorded protein targets — broad pharmacology

Neomycin
Inhibitor

Bacterial 70S ribosome inhibitor

Acts on a complex — shared with rpsL, rpsR, rpsD +51 more · 1 of 55 recorded protein targets — broad pharmacology

Bacterial 70S ribosome inhibitor

Acts on a complex — shared with rpsL, rpsR, rpsD +51 more · 1 of 55 recorded protein targets — broad pharmacology

Erythromycin
Inhibitor

Bacterial 70S ribosome inhibitor

Acts on a complex — shared with rpsL, rpsR, rpsD +51 more · 1 of 55 recorded protein targets — broad pharmacology

Sisomicin
Inhibitor

Bacterial 70S ribosome inhibitor

Acts on a complex — shared with rpsL, rpsR, rpsD +51 more · 1 of 55 recorded protein targets — broad pharmacology

eravacycline
Inhibitor

Bacterial 70S ribosome inhibitor

Acts on a complex — shared with rpsL, rpsR, rpsD +51 more · 1 of 55 recorded protein targets — broad pharmacology

Tetracycline
Inhibitor

Bacterial 70S ribosome inhibitor

Acts on a complex — shared with rpsL, rpsR, rpsD +51 more · 1 of 55 recorded protein targets — broad pharmacology

ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.

Show remaining trials (24)

RECRUITING · via Azithromycin · NCT04381936

COMPLETED · via Doxycycline · NCT03479502

ClinicalTrials.gov via the drug-target graph.

What's happening now

31

Recent activity around this target, drawn from one canonical event stream. Every item is reached through 8 drugs that target this protein, so each event is news about that drug rather than about the protein directly.

  1. Industry development2026-07-23
    Fe-doped BiVO4/g-C3N4 heterojunction for efficient tetracycline degradation under low-intensity UV irradiation

    Nature — Environmental Sciences · news · via Tetracycline

  2. Label change2026-06-12

    Label change: DOXYCYCLINE (ANDA204234)

    fda · regulatory · fda · via Doxycycline

  3. Label change2025-04-25

    Label change: DOXYCYCLINE (ANDA204234)

    fda · regulatory · fda · via Doxycycline

  4. Label change2025-04-25

    Label change: DOXYCYCLINE (ANDA204234)

    fda · regulatory · fda · via Doxycycline

  5. Label change2025-03-31

    Label change: DOXYCYCLINE (ANDA207757)

    fda · regulatory · fda · via Doxycycline

  6. New publication2024-09-27
    Impact of pneumococcal conjugate vaccines on invasive pneumococcal disease-causing lineages among South African children.

    Nature communications · 2024 · 13 citations · Europe PMC · via Erythromycin

  7. New publication2024-01-30
    Guidelines of care for the management of acne vulgaris.

    Journal of the American Academy of Dermatology · 2024 · 236 citations · Europe PMC · via Doxycycline

  8. New publication2021-05-02
    New Antibiotics for Multidrug-Resistant Bacterial Strains: Latest Research Developments and Future Perspectives.

    Molecules (Basel, Switzerland) · 2021 · 302 citations · Europe PMC · via Sisomicin

  9. Safety communication2020-12-17

    Drug Safety Update: Erythromycin: update on known risk of infantile hypertrophic pyloric stenosis

    mhra · safety · mhra · via Erythromycin

  10. Safety communication2020-12-17

    Drug Safety Update: Erythromycin: caution required due to cardiac risks (QT interval prolongation); drug interaction with rivaroxaban

    mhra · safety · mhra · via Erythromycin

  11. New publication2020-09-01
    Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19).

    JAMA cardiology · 2020 · 465 citations · Europe PMC · via Azithromycin

  12. Label change2020-07-08

    Label change: DOXYCYCLINE (ANDA207757)

    fda · regulatory · fda · via Doxycycline

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.